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Abstract
Background: Major depressive disorder afflicts an estimated 17% of individuals during their lifetimes at tremendous
suffering and costs. Cognitive therapy may be an effective treatment option for major depressive disorder, but the effects
have only had limited assessment in systematic reviews.
Methods/Principal Findings: Cochrane systematic review methodology, with meta-analyses and trial sequential analyses of
randomized trials, are comparing the effects of cognitive therapy versus ‘treatment as usual’ for major depressive disorder. To
be included the participants had to be older than 17 years with a primary diagnosis of major depressive disorder. Altogether,
we included eight trialsrandomizing a total of 719 participants. Alleight trials had high risk of bias. Four trialsreported data on
the 17-item Hamilton Rating Scale for Depression and four trials reported data on the Beck Depression Inventory. Meta-
analysis on the data from the Hamilton Rating Scale for Depression showed that cognitive therapy compared with ‘treatment
as usual’ significantly reduced depressive symptoms (mean difference 22.15 (95% confidence interval 23.70 to 20.60;
P,0.007, no heterogeneity)). However, meta-analysis with both fixed-effect and random-effects model on the data from the
Beck Depression Inventory (mean difference with both models 21.57 (95% CL 24.30 to 1.16; P=0.26, I
2=0) could not confirm
the Hamilton Rating Scale for Depression results. Furthermore, trial sequential analysis on both the data from Hamilton Rating
Scale for Depression and Becks Depression Inventory showed that insufficient data have been obtained.
Discussion: Cognitive therapy might not be an effective treatment for major depressive disorder compared with ‘treatment
as usual’. The possible treatment effect measured on the Hamilton Rating Scale for Depression is relatively small. More
randomized trials with low risk of bias, increased sample sizes, and broader more clinically relevant outcomes are needed.
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Introduction
According to the WHO, major depressive disorder is the second
largest healthcare problem worldwide in terms of disability caused
by illness [1]. It afflicts an estimated 17% of individuals during
their lifetimes at tremendous cost to the individual and society
[2,3], and roughly a third of all depressive disorders take a chronic
course [4,5]. Compared to other medical disorders, major depres-
sive disorder causes the most significant deterioration in individual
life quality [6]. Approximately 15% of depressive patients will
commit suicide over a 10 to 20 year period [7].
Antidepressant medication remains the mainstay in the treat-
ment of depression [8]. However, meta-analyses have shown that
newer antidepressants presumably only obtain beneficial effect in
severely depressed patients, and this effect seems to be clinically
small [9,10]. Antidepressants might, however, decrease the risk of
relapse [11]. The therapeutic benefits of antidepressants seem to
be limited and this raises the question if there are other effective
treatments for this serious illness?
Aaron T. Beck originally developed cognitive therapy for
depression [12]. Beck believed that critical life events could
accentuate hidden negative beliefs, which could generate nega-
tive automatic thoughts. These negative thoughts could lead to
symptoms of depression, which then could reinforce more negative
automatic thoughts. The main goal of the ‘cognitive model of
depression’ is to correct these negative beliefs and thoughts in
order to treat the depressive symptoms [12]. A Cochrane review
shows that cognitive therapy has a preventive effect against recur-
rent depression, and that this effect clearly surpasses the preventive
effects of antidepressant medication [13]. Furthermore, cognitive
therapy appears to be an effective treatment for major depressive
disorder [14], but we were unable to find any meta-analysis with
Cochrane methodology [15] examining the effect of cognitive
therapy versus ‘treatment as usual’ for major depressive disorder.
Methods
We conducted our systematic review of randomized clinical
trials involving meta-analysis [15] and trial sequential analysis
[16,17] to answer the question: what are the beneficial and
harmful effects of cognitive therapy versus ‘treatment as usual’ in
the treatment of major depressive disorder? We used assessment of
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22890bias risk to reduce systematic errors [15], and trial sequential
analysis to reduce the risk of random errors [16,17].
For details regarding the methodology please consult our
protocol published on our website (www.ctu.dk) in February 2010
before we began systematic literature searches in all relevant
databases, data-extraction, and analysis [18].
In short, we included all randomized clinical trials comparing
the effect of cognitive therapy alone or in combination with any
co-intervention versus ‘treatment as usual’ alone or in combination
with a similar co-intervention. These co-interventions had to be
administered equally in both intervention groups. The trials were
included irrespective of language, publication status, publication
year, and publication type - based on searches in The Cochrane
Library’s CENTRAL, MEDLINE via PubMed, EMBASE,
Psychlit, PsycInfo, and Science Citation Index Expanded. The
timeframe for the search was all trials published before February
2010.
To be included, participants had to be older than 17 years, with
a primary diagnosis of major depressive disorder. Trials were only
included if the diagnosis of depression was based on one of the
standardized criteria, such as ICD 10 [19], DSM III [20], DSM
III-R [21], or DSM IV [22]. Comorbidity with other psychiatric
diagnoses was not an exclusion criterion. The following types of
trials were excluded:
N Trials focusing on depressed participants with comorbid
serious somatic illness, e.g., myocardial infarction, multiple
sclerosis, cerebral stroke, cancer, etc.
N Trials focusing on ‘late life’ depression or depression in the
elderly, most often participants over 65 years.
N Trials focusing on pregnancy related depression, e.g., postpar-
tum depression, postnatal depression, etc.
N Drug or alcohol dependence related depression.
These exclusions were conducted because we expect partici-
pants in such trials to respond differently to standardized psycho-
therapy than other depressed patients, and these types of depressed
patients are traditionally examined in separate trials [23–26].
Interventions
Cognitive therapy. Cognitive therapy and cognitive-
behavioral therapy are collective terms for a range of different
forms of interventions and it is difficult to find a simple definition,
which adequately describes this psychotherapeutic method.
However, we selected the following criteria from Beck et al.,
1979 as being necessary for the intervention to be classified as
‘cognitive therapy’ [12]:
1. That the intervention seeks to link thoughts, feeling and
behavior, and relates these to the depressive symptoms.
2. That the intervention seeks to record and correct irrational
thoughts or behavioral patterns, and relates this to the
depressive symptoms.
3. That the intervention seeks to teach the patient alternative
methods of thinking or behaving, and to be able to relate this to
the depressive symptoms.
4. That the intervention is undertaken face-to-face either
individually or in a group.
We accepted any co-intervention to cognitive therapy as long as
this co-intervention was similar and administered equally to the
experimental group (cognitive therapy) and the control group
(‘treatment as usual’).
Furthermore, the trials had to present a treatment manual and
had to document adherence to the treatment manual in order for
the intervention to be classified as ‘adequately defined’. All other
trials using the term ‘cognitive therapy’ or ‘cognitive-behavioral
therapy’ were included, but the intervention was classified as ‘not
adequately defined’.
‘Treatment as usual’. For ‘treatment as usual’ control
interventions we accepted any non-specific treatments described
as: ‘treatment as usual’, ‘standard care’, or ‘clinical management’,
etc. To be included the ‘treatment as usual’ intervention had to
include some kind of non-specific supportive treatment.
We accepted any co-intervention to ‘treatment as usual’ as long
as this co-intervention was similar and administered equally to the
experimental group (cognitive therapy) and the control group
(‘treatment as usual’).
Trial selection
Three of the review authors (JJ, JLH, and OJS) independently
selected relevant trials. If a trial was selected by three or two of the
three, it was included. If a trial was identified only by one of the
three, it was discussed whether the trial should be included.
Excluded trials were entered on a list, stating the reason for
exclusion.
Data extraction
Data were extracted for trial design, bias risk, and outcomes
independently by two authors (JJ and JLH). Disagreements were
resolved by discussion or through arbitration (CG). We used the
instructions in The Cochrane Handbook for Systematic Reviews
of Interventions [15] in our evaluation of the methodology and
hence bias risk of the trials. We assessed the bias risk in respect to
generation of the allocation sequence; allocation concealment;
blinding; intention-to-treat analysis; dropouts; reporting of out-
come measures; economic bias; and academic bias. These
components enable classification of the included trials into trials
with ‘low risk of bias’ or with ‘high risk of bias’. The trials were
overall classified as ‘high risk of bias’ if one or more of the above
components was ‘uncertain’ or ‘high risk of bias’ [15,27–29]. This
classification is important because trials with ‘high risk of bias’ may
overestimate positive intervention effects and underestimate
negative intervention effects [15,27,28,30], and we wanted to
relate the validity of our results to the risk of bias in the included
trials.
Primary outcome measures
Depressive symptoms. Our primary outcome was the mean
value on the Hamilton Rating Scale for Depression (HDRS) [31],
Beck Depression Inventory (BDI) [32], or Montgomery-Asberg
Depression Rating Scale (MADRS) [33] at follow-up. We included
data based on the total number of randomized patients (intention-
to-treat analysis)ifthesedata werereported.Weplanned toestimate
the therapeutic follow-up responses at two time points:
N At cessation of treatment: The trials original primary choice of
completion date was used. This was the most important
outcome measure time point in this review.
N At maximum follow-up.
Adverse events. We classified adverse events as serious or
non-serious. Serious adverse events were defined as medical events
that are life threatening; result in death; disability or significant loss
of function; that cause hospital admission or prolonged hospitali-
zation; a hereditary anomaly; or fetal injury [34]. All other adverse
events (that is, events that have not necessarily had a causal
Cognitive Therapy for Depression
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cessation of the treatment) were considered as non-serious events.
Quality of life. We included any measure of quality of life,
noting each assessment measure.
Secondary outcome measures
Participants without remission. The proportion of parti-
cipants not having achieved remission was our first secondary
outcome. We included data based on the total number of
randomized participants (intention-to-treat analysis) - if possible.
If the results were not based on the total number of participants,
we performed an intention-to-treat analysis assuming that the
participants not included in the results did not achieve remission
[15]. We pragmatically defined remission as HDRS of less than 8,
BDI less than 10, or MADRS less than 10 [31–33].
Participants with suicidal inclination. Number of suicides,
suicide attempts, or suicide inclination was other secondary outcomes.
Statistical methods
This meta-analysis was undertaken according to the recom-
mendations stated in The Cochrane Handbook for Systematic
Reviews of Interventions [15]. In analyzing continuous outcomes
with both fixed-effect and with random-effects models, we used the
mean difference (MD) with a 95% confidence interval. We used
RevMan version 5.0 [35]. We did not use ‘standardized mean
difference’ so each outcome measure was analyzed separately. We
did not adjust the outcome variables at follow-up according to the
baseline values [15].
We used the risk odds ratio (OR) with a 95% confidence
interval to estimate intervention effects on dichotomous outcomes
with both fixed-effect and with random-effects models [35].
We performed ‘test of interaction’ [36] for all subgroup analyses
[18].
For primary outcome measures, we also conducted trial
sequential analyses. In order to calculate the required information
size and the cumulative Z-curve’s eventual breach of relevant trial
sequential monitoring boundaries [16,17], the required informa-
tion size of the trial sequential analysis was based on a type I error
of 5%, a beta of 20% (power of 80%), the variance of all the trials
(as no trial had low risk of bias), and a minimal relevant difference
on two points on the HDRS or four points on the BDI.
Results
Search results
Our primary literature search identified 4536 publications.
According to our protocol [18] we excluded 4137 publications on
the basis of the title or abstract, and further 339 citable units were
excluded on the basis of the full publication. These exclusions were
done either because the publications did not relate to cognitive
therapy and major depressive disorder, or because they were not
randomized trials comparing cognitive therapy versus ‘treatment
as usual’. Further 42 publications [37–78] were excluded because
the trial participants or the interventions did not meet our in-
clusion criteria.
Included trials
We included 18 publications [79–96] on eight trials [14,79–
82,84,85,97] randomizing a total of 719 participants (see Figure
S1).
Only five of the trials used an intervention that we classified as
‘adequately defined’ (see above) [14,79,81,82,97]. We classified the
therapists’ level of experience and/or education in three trials as
‘high’ [14,79,81], in two trials as ‘intermediate’ [84,85], and in the
last three as ‘unclear’ [80,82,97].
Two trials used cognitive group therapy as experimental
intervention [80,82], and one trial used both group and individual
therapy [97]. The remaining five trials used only individual
therapy [14,79,81,84,85].
The duration and the extent of the cognitive therapy also varied
in the different trials from eight weekly group sessions [80] to 20
weekly individual sessions [14]. The specific content of the
‘treatment as usual’ interventions were generally not standardized
or not reported, and the duration and extent of the ‘treatment as
usual’ interventions varied greatly between the different trials.
Four of the trials allowed antidepressant medication as a part of
the ‘treatment as usual’ intervention, but it was not reported to
what extent the participants in the four trials received antidepres-
sants. We have described both the experimental and the control
interventions from the included trials in Table 1.
One of the included trials used antidepressants as add-on
therapy in both the experimental group (cognitive therapy) and the
control group (clinical management) [80].
Miranda et al. examined the effect of cognitive therapy versus
community care [97]. The results showed that cognitive therapy
significantly reduced depressive symptoms at cessation of treat-
ment compared with community care. However, the authors did
not report means and SD and did not report data on remission
rates at cessation of treatment. We have written to the authors
requesting the necessary data, but have received no answer.
Therefore, we have not been able to include the results from this
trial in the following meta-analyses. However, the authors did
report rates of remission at six and 12 months follow-up. The
results at six months showed no significant difference regarding
remission. The results at 12 months showed that cognitive therapy
significantly increased the probability of remission compared with
community care (P=0.01).
DeRubeis et al. examined the effect of cognitive therapy versus
clinical management plus a placebo pill [81]. The results did not
differ significantly regarding HDRS score midway through the
intervention period. The authors did not report means and SD, and
did not include assessment at cessation of treatment for theseoutcome
measures. We have written to the authors requesting the necessary
data, but have received no answer. Therefore, we have not been able
to include the results from this trial in the following analysis.
Wiles et al. included participants from primary care who had
not responded to at least six weeks of antidepressant medication
[85]. The participants were randomized to cognitive therapy
versus ‘usual care’. Those who received cognitive therapy had a
mean on BDI 9 points lower than those in the ‘usual care’ group,
suggesting a beneficial effect of cognitive therapy compared with
‘usual care’. The authors did not report means and SD in the
publication. Through e-mail correspondence the authors kindly
reported that they were unable to provide the necessary data, so
we have not been able to include the results from this trial in the
following analysis.
Table 1 summarizes the characteristics of the eight included
trials.
Bias risk
We assessed all eight trials [14,79–82,84,85,97] as having ‘high
risk of bias’ due to unclear or inadequate components as described
in Table 2.
Primary outcome measures
Depressive symptoms at cessation of treatment. Four
trials assessed HDRS as a continuous outcome measure at
Cognitive Therapy for Depression
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cessation of treatment [14,79,80,82].
HDRS. Meta-analysis with the fixed-effect model on the
HDRS data from the four trials [14,79,82,84] show that cognitive
therapy at the end of therapy significantly reduced depressive
symptoms compared with ‘treatment as usual’ (Figure 1) (mean
difference 22.15 HDRS; 95% CI 23.70 to 20.60; P,0.007,
I
2=0). The I
2 statistic describes the percentage of variation across
trials that are due to heterogeneity rather than chance. Meta-
analysis with the random-effects model gave an identical result.
BDI. Meta-analysis with the fixed-effect model on the data
from the four trials [14,79,80,82] using BDI at cessation of
treatment was in agreement with the results from HDRS (mean
difference 26.03 BDI; 95% CI 28.33 to 23.72; P=0.00001,
Table 1. Characteristics of the included trials.
Trial Particiants (randomized) Interventions Outcomes and notes
Elkin et al., 1989 124 outpatients Cognitive therapy (individual, 16–20 weeks) versus pill-
placebo and clinical management clinical management:
(support, encouragement and advice if necessary)
HDRS, BDI, remission
(HDRS,7 & BDI,10)
Scott et al., 1992 60 outpatients Cognitive therapy (individual, 16 weeks) versus general
practitioner care (general practitioner were asked to
manage participants as they normally would, including
referral to other agencies)
HDRS, remission (HDRS,7)
Embling et al., 2002 38 outpatients Cognitive therapy (group, 8 weeks) antidepressants versus
clinical management+ antidepressants antidepressant: not
reported clinical management: weekly 10–20 min sessions
BDI
Miranda et al., 2003 179 outpatients Cognitive therapy (group or individual, 8–16 weeks)
versus community care. Community care: education
about depression and mental health treatments available
HDRS, remission (HDRS,8+50%)
change from baseline). Participants were
low-income young minority women
Verduyn et al., 2003 75 outpatients Cognitive therapy (group, 16 weeks) versus ‘routine
services accessible to participants’
HDRS, BDI
DeRubeis et al., 2005 120 outpatients Cognitive therapy (individual, 16 weeks) versus placebo
pill+clinical management. Clinical management: 10
sessions during 16 weeks
HDRS, remission (HDRS,8) means and
SD not included
Dimidjian et al., 2006 98 outpatients Cognitive therapy (individual, 16 weeks) versus 8 weeks
of clinical management+pill placebo. Clinical management:
6 sessions of 30 minutes
HDRS, BDI
Wiles et al., 2008 25 outpatients Cognitive therapy (individual, 12–20 weekly sessions)
versus usual care. Usual care: no restrictions on the
treatment that patients could receive
BDI, quality of life means and SD not
included. All of the participants had not
responded to antidepressants prior to
randomization
doi:10.1371/journal.pone.0022890.t001
Table 2. Risk of bias.
Allocation
sequence
generation?
Allocation
concealment?
Intention
to treat
analysis? Blinding?
Comparability
of drop-outs in
intervention
groups?
Free of
selective
outcome
measure
reporting?
Free of
economic
bias?
Free of
academic
bias?
Overall
bias
assessment
Elkin
et al., 1989
Unclear Unclear No Unclear yes Yes Yes Unclear High risk of bias
Scott
et al., 1992
Unclear No No Unclear Yes Unclear Yes Unclear High risk of bias
Embling
et al., 2002
Unclear Unclear Yes Unclear Yes Unclear Unclear Unclear High risk of bias
Miranda
et al., 2003
Yes Yes unclear Yes yes Unclear Yes Unclear High risk of bias
Verduyn
et al., 2003
Unclear Yes No Yes No Unclear Yes Unclear High risk of bias
DeRubeis
et al., 2005
Unclear unclear yes Unclear yes Unclear Unclear Unclear High risk of bias
Dimijian
et al., 2006
Yes Unclear No Yes No Unclear No Unclear High risk of bias
Wiles et al.,
2008
Yes Yes Yes Unclear No Unclear Yes unclear High risk of bias
doi:10.1371/journal.pone.0022890.t002
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2=89%). Meta-analysis with the random-effects model showed
that cognitive therapy compared with ‘treatment as usual’ did not
significantly reduce depressive symptoms on BDI (mean difference
24.85; 95% CI 212.08 to 2.39; P,0.19, I
2=89%) (Figure 2).
Due to the substantial heterogeneity on the BDI results we
performed a sensitivity analysis. We excluded the results from
Embling et al. trial and found thereafter no heterogeneity [80].
The possible explanations why the results from Embling et al.
differed from the rest of the included trials [14,79,82] are discussed
below. Meta-analysis with the fixed-effect model on the three
remaining trials [14,79,82] showed that cognitive therapy
compared with ‘treatment as usual’ did not significantly reduce
depressive symptoms on the BDI (mean difference 21.57 (95%
CL 24.30 to 1.16; P=0.26, I
2=0). Meta-analysis with the
random-effects model gave an identical result.
Trial sequential analysis on the HDRS data and the BDI data
showed that ‘insufficient data’ have been obtained to decide if
cognitive therapy is superior to ‘treatment as usual’ (Figures 3 & 4).
Follow-up. Verduyn et al. included maximal follow-up asses-
sment at 12 months after the beginning of treatment on HDRS
and BDI [82]. They found no significant difference between the
different intervention groups on either of outcome measures.
Miranda et al. reported rates of remission at six and 12 months
follow-up [97]. The results are described under ‘Included trials’.
None of the remaining trials included assessment data after the
cessation of treatment.
Adverse events. DeRubeis et al. reported that two parti-
cipants dropped out due to adverse events, but the particulars about
the events were not reported [81]. Both participants were from the
control group receiving placebo. None of the remaining trials
reported on adverse events.
Quality of life. Wiles et al. assessed quality of life as outcome
measure [85]. They found no significant difference between the
two intervention groups at cessation of treatment. Means, SD, or
choice of outcome measure for quality of life was not reported.
None of the remaining trials used any assessment of quality of life.
Secondary outcome measures
Participantswithoutremission. Two trials [14,84] reported
the proportion of participants without remission at cessation of
treatment as a dichotomous outcome measure. We had planned to
define remission as HDRS less than 8, BDI less than 10, or
MADRS less than 10. However, this was not possible, so we
adopted the slightly different definitions used by the two trials. Elkin
et al. defined remission in two different ways: as HDRS,7a n d
BDI,10 [14]. Scott et al. defined remission as HDRS,7 [84].
Meta-analysis on the data from the two trials reporting on
HDRS [14,84] showed that cognitive therapy compared with
‘treatment as usual’ did not significantly decrease the risk of ‘no
remission’ (odds ratio of ‘no remission’ in favor of cognitive
therapy of 0.71 (95% CI, 0.38 to 1.32; P=0.28, I
2=56%)
(Figure 5). The BDI data from Elkin et al. also showed that
cognitive therapy compared with ‘treatment as usual’ did not
significantly decrease the risk of ‘no remission’ (P=0.33) [14].
Suicide inclination, suicide attempts, or suicides. None
of the trials reported on suicide inclination, suicide attempts, or
suicides.
Subgroup analyses
In subgroup analyses stratified according to the type of therapy
(group compared to individual therapy) and to the therapists’ level
of education and experience (‘high’ compared to ‘intermediate’
and ‘unclear’), ‘test of interaction’ [36] on the HDRS data showed
no difference in treatment effect between these subgroups (setting
P=0.83; education and experience P=0.69). Furthermore, we
found no heterogeneity in our meta-analysis result on the HDRS
data, This indicates that these factors do not seem to influence the
effect of cognitive therapy measured on the HDRS.
Figure 1. The effect of cognitive therapy versus ‘treatment as usual’ at cessation of treatment on the Hamilton Rating Scale for
Depression (HDRS).
doi:10.1371/journal.pone.0022890.g001
Figure 2. The effect of cognitive therapy versus ‘treatment as usual’ at cessation of treatment on the Beck Depression Inventory
(BDI).
doi:10.1371/journal.pone.0022890.g002
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bias [18]. However, as all trials were classified as ‘high risk of bias’
it was not possible to conduct this analysis.
Discussion
The results of our systematic review with meta-analysis (fixed-
effect model and random-effects model) indicate that cognitive
therapy is likely to significantly reduce depressive symptoms on
HDRS compared with ‘treatment as usual’. The result of our
meta-analysis after a sensitivity analysis on the BDI data (fixed
effect-model and random-effects model) did, however, not show a
significant reduction on the BDI. Trial sequential analysis on both
on the HDRS data and BDI data showed that insufficient data
have been obtained. Finally, cognitive therapy compared with
‘treatment as usual’ did not significantly decrease the risk of ‘no
remission’. BDI is a ‘self report’ questionnaire and HDRS is an
observer dependant interview. This enables a more objective and
blinded assessment of the degree of depressive symptoms with
HDRS, but only three trials were assessed as having adequate
blinding. We believe the neutral effects on BDI combined with the
small effects on HDRS suggest that cognitive therapy may not
have dramatic effects.
Trial sequential analysis is a statistical analysis that is adjusting
the type I error level to decrease the risk of random errors due to
sparse data and multiple testing on accumulating data. Therefore,
is a more robust analysis than traditional cumulative meta-analysis
[16,98]. Our analysis demonstrates that we lack firm evidence on
the intervention effect of cognitive therapy versus ‘treatment as
usual’ for major depressive disorder. The trial sequential analysis
result also indicates that in order to detect or reject an intervention
effect with a minimal relevant difference of two points on HDRS,
an information size of 742 participants may be needed.
The heterogeneity on the results on the BDI data is generated
by the results from one trial [80]. The results from the Embling et
al. trial showed that cognitive therapy compared with the control
intervention, decreased the BDI score with a much greater effect-
size than the rest of the trials. Embling et al. was the only of the
included trials using antidepressants as add-on therapy as part of
both the experimental and control interventions [80]. Although
Figure 3. Trial sequential analysis of the cumulative meta-analysis of the effect of cognitive therapy versus ‘treatment as usual’ for
major depressive disorder on the Hamilton Rating Scale for Depression (HDRS). The required information size of 742 participants is
calculated based on an intervention effect compared with ‘treatment as usual’ of 2 points on the HDRS, a variance of 94.5 on the mean difference, a
risk of type I error of 5% and a power of 80%. With these presumptions, the cumulated Z-curve (blue curve) do not cross the trial sequential
monitoring boundaries (red inner sloping lines) implying that there is no firm evidence for a beneficial effect of cognitive therapy compared with
‘treatment as usual’.
doi:10.1371/journal.pone.0022890.g003
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examine differences between intervention groups, this finding
suggests that adding antidepressants to cognitive therapy might
have a greater effect compared to cognitive therapy alone. The
Embling et al. trial did only report results on the BDI which is a
self report questionnaire hindering a blinded assessment of the
depressive symptoms. Furthermore, the trial had only two out of
the eight bias risk components classified as ‘low risk of bias’
increasing the risk of biased results. These considerations may
support the validity of our post-hoc sensitivity analysis excluding
the results from this trial in our meta-analysis.
Strengths
The present review has a number of strengths. Our protocol [18]
was published before we began the systematic literature searches in
all relevant databases, data extraction, and data analyses. Data was
extracted by two independent authors minimizing the risk of
inaccurate data-extraction, and we assessed the risk of bias in all
Figure 4. Trial sequential analysis of the cumulative meta-analysis of the effect of cognitive therapy versus ‘treatment as usual’ for
major depressive disorder on the Beck Depression Inventory (BDI). The required information size of 462 participants is calculated based on
an intervention effect compared with ‘treatment as usual’ of 4 points on the BDI, a variance of 235.4 on the mean difference, a risk of type I error of
5% and a power of 80%. With these presumptions, the cumulated Z-curve (blue curve) do not cross the trial sequential monitoring boundaries (red
inner sloping lines) implying that there is no firm evidence for a beneficial effect of cognitive therapy compared with ‘treatment as usual’.
doi:10.1371/journal.pone.0022890.g004
Figure 5. Effect of cognitive therapy versus ‘treatment as usual’ on ‘no remission’ at cessation of treatment.
doi:10.1371/journal.pone.0022890.g005
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Reviews of Interventions [15]. We meta-analyzed data both with
fixed-effect andrandom-effectsmodels.Furthermore,weperformed
trial sequential analysis to control for random errors [16,98].
Limitations
Our systematic review has a number of limitations. Only one of
the included trials was assessed as being free of ‘selective outcome
measure reporting bias’ [15]. There is therefore a risk of within-
study selective outcome reporting in seven of the eight included
trials. All eight trials had an overall assessment as ‘high risk of bias’
- so our results may be questionable. Moreover, for the positive
findings trial sequential analysis showed that we could not exclude
the risk of random errors [16,98]. Due to the limited number of
included trials we did not perform a funnel plot or other analysis to
explore the risk of publication bias [99]. Other meta-analyses have
shown that publication bias significantly has influenced the results
from former publications [9]. It is a further limitation that we are
not able to assess the risk of publication bias.
Cognitive therapy is generally considered to be one of most
evidence-based forms of psychotherapy and we expected to find
more randomized trials. However, our literature search did only
identify eight trials with a limited number of participants. Only
four of the eight trials reported mean and SD for HDRS, and only
four of the eight trials reported means and SD for BDI. Our results
show that cognitive therapy compared with ‘treatment as usual’
did not significantly decrease the risk of ‘no remission’, but only
two out of the eight included trials reported relevant data on
remission at end of treatment, while one reported remission rates
at six and 12 months follow-up. We might find different results if
we had more relevant randomized trials or if we made our
inclusion criteria broader (e.g., including trials comparing cogni-
tive therapy with antidepressants).
Only two of the trials included assessments after the cessation of
treatment. Therefore it is not clear whether cognitive therapy has
an effect on depressive symptoms in the longer term.
Only one of the trials reported measures of quality of life.
Outcome measures of quality of life are generally not standardized
and thoroughly validated [100]. The use of standardized outcome
measures for quality of life in research has been limited by
difficulties in administering and scoring quality of life [100], but
quality of life can be used as a valid outcome measure [29,100].
The effect of cognitive therapy on quality of life compared with
‘treatment as usual’ is therefore unclear.
Only one of the included trials reported on some adverse events
and none of the trials included records of suicide inclination,
suicide attempts, or suicides. Typically adverse events are not
reported as thoroughly as beneficial outcome measures [101].
Some psychological interventions might have harmful effects. E.g.,
psychological debriefing for preventing post-traumatic stress
disorder in some clinical trials has showed to have a harmful
effect [102]. Possible harmful effects of this kind of therapy are
therefore not thoroughly examined.
A number of subgroups of depressed patients (e.g., inpatients)
were not assessed in the eight trials we identified and included.
These subgroups may react differently to psychotherapy and our
results cannot be generalized to other than the patient groups
included in the eight trials. Moreover, the extent and form of the
‘treatment as usual’ intervention varied greatly and the specific
content of the ‘treatment as usual’ interventions were generally not
standardized or reported (Table 1). E.g., four of the trials allowed
antidepressants as a part of the ‘treatment-as-usual’ intervention
but the extent of the antidepressants medication were not reported
or controlled for. Due to the unclear content of the control
interventions it is possible that the participants in the control
groups actually received some kind of psychotherapeutic inter-
vention - possibly including cognitive therapeutic interventions.
Furthermore, the duration and extent of the cognitive therapy
interventions did also vary in the different trials (Table 1).
Although head-to-head comparisons are needed in order to
thoroughly examine a difference in effect between two interven-
tions, we found no heterogeneity on our results on either HDRS or
BDI (after sensitivity analysis) indicating that there might be no
difference in effect between the different interventions. Moreover,
only five of the included trials presented a treatment manual and
documented adherence to the treatment manual for the cognitive
experimental intervention. The possible difference between
cognitive therapy and ‘treatment as usual’ could be due to this
manualization rather than to the specific cognitive technics. These
aspects are further limitations and make our results less generally
applicable.
As mentioned, only five of the included trials used an
intervention that we classified as ‘adequately defined’, i.e., using
and documenting the use of a therapeutic manual. And although
we did not find any heterogeneity on the HDRS data it is
imperative in clinical trials that the interventions are adequately
defined and described [103]. Factors like personal style, commu-
nication skills, and personality of the therapist evidently will
influence the way psychotherapy is delivered [104]. It is difficult to
describe and control for these subjective factors, and this makes it
even more important to relate the therapy to a treatment manual.
Otherwise it is unclear what kind of intervention the participants
were receiving, and it is difficult to apply any result in clinical
practice.
Implications
Our meta-analysis show that the possible benefit from this
relatively extensive treatment compared with ‘treatment as usual’
was only a few points on the HDRS. From a clinical point of view
it could be argued that this possible benefit is not clinically relevant
- especially if you relate this mean difference to the extent and
length of the intervention. Furthermore, the NICE guidelines
[105] recommend that a mean difference on 3 on the HDRS are
needed in order for a intervention to be considered significantly
clinically effective [105]. We found a mean difference on 2.15 on
the HDRS. Other meta-analyses have used this definition to judge
if an intervention should be considered clinically effective [9].
In our protocol [18] we chose HDRS, BDI, and MADRS as our
primary outcome measures because we expected that most trials
would only use these assessment measures, and HDRS has in
many years been the gold standard to quantify depressive sym-
ptoms in clinical trial [106]. Severity of depression as measured by
the total HDRS score has failed to predict suicide attempts [107],
and some publications have questioned the usefulness of the
HDRS and concluded that the scale is psychometrically and
conceptually flawed [106]. MADRS and BDI probably corre-
spond to HDRS [108,109]. We do not know if these scales are able
to assess any potential beneficial effects of cognitive therapy. From
the patient’s point of view, a score on HDRS, BDI, or MADRS is
not necessarily a measure of the degree of suffering, and other
assessment methods could demonstrate a more or less substantial
effect of any given intervention for depression. The HDRS during
40 years has been the gold standard to quantify depressive
symptoms in clinical trials [106]. There is a need for trials assessing
and reporting more clinically relevant outcome measures. We
believe such assessment methods should be reporting on adverse
events and suicidal tendencies, or assessment methods that correspond
to clinically relevant outcomes seen from the patient’s point of view.
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22890Future research should focus on comparing the effect of
cognitive therapy versus ‘treatment as usual’ for major depressive
disorder. First and foremost such trials should be conducted with
longer follow-up, low risk of bias (systematic errors) and low risk of
random errors (play of chance) [110]. Such trials should also
report on adverse events, suicide inclination, suicide attempts, and
numbers of suicides and the specific content of the ‘treatment as
usual’-interventions should be reported. There seems to be a need
for a new gold standard assessment method other than HRDS to
assess depressive symptoms.
Conclusions
Cognitive therapy might not be an effective intervention for
major depressive disorder compared with ‘treatment as usual’. The
possible treatment effect measured on the HDRS is relatively
small. More randomized trials with low risk of bias, low risk of
random errors, and longer follow-up are needed. Future trials
should assess the effect of cognitive therapy on adverse events,
suicidal tendencies, quality of life, and other clinically relevant
outcomes.
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